Kinesins and Cancer (eBook)
X, 271 Seiten
Springer Netherlands (Verlag)
978-94-017-9732-0 (ISBN)
This interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development.
Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future.
The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail.
This interdisciplinary volume collates research work on kinesins and cancer. Authors attempt to validate members of the kinesin superfamily as potential targets for drug development in cancer chemotherapy. The work begins by highlighting the importance of kinesins, summarising current knowledge and how they are shown to be crucial for mitosis. Chapters go on to explore how this family of proteins are emerging as a novel target for chemotherapeutic intervention and drug development.Readers will learn how kinesins travel along microtubules to fulfill their many roles in intracellular transport or cell division. Several compounds that inhibit two mitotic kinesins (called Eg5 and CENP-E) have entered Phase I and II clinical trials and are explored in these chapters. Additional mitotic kinesins are currently being validated as drug targets, raising the possibility that the repertoire of kinesin-based drug targets may expand in the future.The book is suitable as a reference standard for the field of kinesins and cancer. It will interest those in academia and pharmaceutical companies, and anyone with an interest in the medical relevance of these proteins, which cutting edge methodologies are now enabling us to understand in astonishing detail.
Preface 1 The kinesin superfamilyKristen J. Verhey, Jared C. Cochran and Claire E. Walczak 2 The discovery and development of Eg5 inhibitors for the clinicJames A.D. Good, G. Berretta, Nahoum G. Anthony and Simon P.Mackay 3 Mechanism of action of Eg5 inhibitorsRobert A.Cross 4 Clinical trials of mitotic kinesin inhibitorsSteven S.Rosenfeld 5 Kif15; a useful target for anti-cancer therapy?Roy G.H.P. van Heesbeen and Rene H.Medema 6 Down-regulating CENP-E activity: for better or for worseJulien Espeut and ArianeAbrieu7 The human kinesin-14 motor KifC1/HSET is an attractive anti-cancer drug targetVaishali Pannu, Padmashree C.G. Rida and Ritu Aneja 8 Kinesin-13 Microtubule Depolymerizing Proteins as targets for cancer therapyAnutosh Ganguly and Fernando Cabral 9 Chromokinesins in genome maintenance and cancerManjari Mazumdar and Tom Misteli 10 Kif14: a clinically relevent kineisn and potential target for cancer therapyBrigitte L. Theriault and Timothy W. Corson 11 Kinesin-8 members and their potnetial as biomarker or therapeutic targetThomas U. Mayer and Silke Hauf 12 The kinesin-6 members MKLP1, MKLP2 and MPP1Ryan D. Baron and Francis Barr 13 Non-motor spindle proteins as cancer chemotherapy targetsBob Margolis and Mythili Yenjerla 14 Inhibitors of mitotic kinesins for cancer treatment: consequences for neuronsOlga I. Kahn and Peter Baas Index
| Erscheint lt. Verlag | 2.3.2015 |
|---|---|
| Zusatzinfo | X, 271 p. 50 illus., 32 illus. in color. |
| Verlagsort | Dordrecht |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Medizin / Pharmazie ► Studium | |
| Naturwissenschaften ► Biologie ► Biochemie | |
| Naturwissenschaften ► Chemie | |
| Technik | |
| Schlagworte | Cancer Chemotherapy • Human mitotic kinesins • Mitotic spindle as a validated target • Molecular motors • Protein-Ligand Interactions • Target validation/drug development |
| ISBN-10 | 94-017-9732-3 / 9401797323 |
| ISBN-13 | 978-94-017-9732-0 / 9789401797320 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 8,8 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
